Peptide Library

Semaglutide — a GLP-1 receptor agonist used in FDA-approved medicines for type 2 diabetes and chronic weight management. Compounded versions are not FDA-approved and require individualized clinical review.

Tirzepatide — a dual GIP/GLP-1 receptor agonist used in FDA-approved medicines for type 2 diabetes and chronic weight management. Compounded versions are not FDA-approved.

Cagrilintide — a long-acting amylin analogue being studied for weight management. It is investigational, is not FDA-approved, and FDA states it cannot be used in compounding under federal law.

Retatrutide — an investigational triple GIP/GLP-1/glucagon receptor agonist. It is not FDA-approved, and FDA states it cannot be used in compounding under federal law.

CJC-1295 (no DAC) — a short-acting GHRH analogue studied for its effect on pulsatile growth-hormone signaling; not FDA-approved.

Ipamorelin — a growth-hormone secretagogue studied for selective ghrelin-receptor activity; not FDA-approved.

CJC-1295 + Ipamorelin — a research blend combining two growth-hormone signaling pathways; not FDA-approved.

Sermorelin — a GHRH analogue used to stimulate the body’s own growth-hormone release; current compounded preparations are not FDA-approved.

Tesamorelin — a GHRH analogue available in an FDA-approved medicine for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Other uses and custom preparations are not FDA-approved.

Tesamorelin + Ipamorelin — a custom blend studied for combined GHRH and ghrelin-receptor signaling; the combination is not FDA-approved.

IGF-1 LR3 — a long-acting IGF-1 analogue used in laboratory research; not FDA-approved for human use.

BPC-157 — a synthetic research peptide studied in preclinical models of tissue repair and inflammation. Human evidence is limited, and it is not FDA-approved.

TB-500 — a thymosin beta-4 fragment studied in preclinical healing and cell-migration research. Human safety data are limited, and it is not FDA-approved.

Wolverine Blend — combines BPC-157 and TB-500 for research-oriented repair signaling; the blend is not FDA-approved.

GLOW Blend — combines BPC-157, TB-500 and GHK-Cu in a custom research formulation; not FDA-approved.

KLOW Blend — combines KPV, BPC-157, TB-500 and GHK-Cu in a custom research formulation; not FDA-approved.

KPV — a short alpha-MSH-derived peptide studied for inflammatory signaling. FDA reports no identified human exposure data for compounded KPV; it is not FDA-approved.

Semax — a synthetic peptide studied for neurologic and cognitive pathways. U.S. human safety information is limited, and it is not FDA-approved.

Selank — a synthetic peptide studied for anxiety-related and neuroimmune pathways. Evidence remains limited, and it is not FDA-approved.

DSIP (Emideltide) — a peptide studied for sleep-related signaling. FDA reports insufficient safety information for proposed compounded routes; it is not FDA-approved.

Dihexa — a research compound studied for neurotrophic signaling. FDA reports no identified human exposure data for dihexa acetate; it is not FDA-approved.

Epitalon — a synthetic tetrapeptide studied in aging-related research. Human safety information is limited, and it is not FDA-approved.

MOTS-c — a mitochondrial-derived peptide studied for metabolic and cellular signaling. FDA reports no identified human exposure data for compounded products; it is not FDA-approved.

SS-31 (Elamipretide) — a mitochondria-targeted peptide. An FDA-approved elamipretide medicine exists only for improving muscle strength in people with Barth syndrome weighing at least 30 kg; other uses or preparations are not FDA-approved.

FOXO4-DRI — an experimental peptide studied in cellular-senescence research. Evidence is preclinical, and it is not FDA-approved.

Thymosin Alpha-1 (TA-1) — an immune-signaling peptide studied in a range of infectious and immune conditions. It is not FDA-approved in the United States, and FDA describes available safety information for compounded use as inadequate.

LL-37 — a naturally occurring antimicrobial peptide studied for innate immune signaling. It is not FDA-approved, and compounded use raises important safety and quality questions.

Bremelanotide (PT-141) — a melanocortin receptor agonist. An FDA-approved bremelanotide medicine exists for acquired, generalized hypoactive sexual desire disorder in certain premenopausal women; other uses or preparations are not FDA-approved.

Kisspeptin — a reproductive-signaling peptide studied for its role in the hypothalamic-pituitary-gonadal axis. Compounded kisspeptin products are not FDA-approved, and available safety data are limited.

GHK-Cu — a naturally occurring copper-binding peptide used in cosmetic research and topical skin-care formulations. Injectable preparations are not FDA-approved and raise additional safety and quality concerns.

MT-1 (Melanotan I / Afamelanotide-related) — a melanocortin peptide associated with pigmentation signaling. An FDA-approved afamelanotide implant exists only for a specific rare light-sensitivity disorder; other forms and uses are not FDA-approved.

MT-2 (Melanotan II) — an investigational melanocortin peptide associated with pigmentation and sexual-response signaling. It is not FDA-approved, and FDA notes reports of serious adverse events.